BE2023C542I2 - - Google Patents
Download PDFInfo
- Publication number
- BE2023C542I2 BE2023C542I2 BE2023C542C BE2023C542C BE2023C542I2 BE 2023C542 I2 BE2023C542 I2 BE 2023C542I2 BE 2023C542 C BE2023C542 C BE 2023C542C BE 2023C542 C BE2023C542 C BE 2023C542C BE 2023C542 I2 BE2023C542 I2 BE 2023C542I2
- Authority
- BE
- Belgium
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1069—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from blood cells, e.g. the cancer being a myeloma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0413320A FR2879204B1 (fr) | 2004-12-15 | 2004-12-15 | Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b. |
PCT/FR2005/003123 WO2006064121A2 (fr) | 2004-12-15 | 2005-12-14 | Anticorps cytotoxique dirige contre les proliferations hematopoïetiques lymphoïdes de type b |
Publications (1)
Publication Number | Publication Date |
---|---|
BE2023C542I2 true BE2023C542I2 (xx) | 2025-02-07 |
Family
ID=34953790
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BE2023C542C BE2023C542I2 (xx) | 2004-12-15 | 2023-11-21 |
Country Status (16)
Country | Link |
---|---|
US (2) | US9234045B2 (xx) |
EP (2) | EP2949674A1 (xx) |
JP (2) | JP4999699B2 (xx) |
KR (3) | KR101418695B1 (xx) |
CN (1) | CN101115772B (xx) |
AU (1) | AU2005315534B2 (xx) |
BE (1) | BE2023C542I2 (xx) |
BR (1) | BRPI0519044B8 (xx) |
CA (1) | CA2590303C (xx) |
DK (1) | DK1824887T3 (xx) |
ES (1) | ES2588161T3 (xx) |
FR (2) | FR2879204B1 (xx) |
IL (1) | IL183947A0 (xx) |
NL (1) | NL301242I2 (xx) |
PL (1) | PL1824887T3 (xx) |
WO (1) | WO2006064121A2 (xx) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
EP1776384B1 (en) | 2004-08-04 | 2013-06-05 | Mentrik Biotech, LLC | Variant fc regions |
FR2879204B1 (fr) * | 2004-12-15 | 2007-02-16 | Lab Francais Du Fractionnement | Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b. |
FR2879605B1 (fr) * | 2004-12-16 | 2008-10-17 | Centre Nat Rech Scient Cnrse | Production de formats d'anticorps et applications immunologiques de ces formats |
EP2522396A1 (en) | 2005-02-03 | 2012-11-14 | TopoTarget UK Limited | Combination therapies using HDAC inhibitors |
BRPI0610128B1 (pt) | 2005-05-13 | 2021-12-07 | Topotarget Uk Limited | Composição farmacêutica, e, uso de uma composição |
PT1912675E (pt) | 2005-07-25 | 2014-05-09 | Emergent Product Dev Seattle | Moléculas de ligaçao especificas para cd37 e especificas para cd20 |
JP5377968B2 (ja) | 2005-11-10 | 2013-12-25 | トポターゲット ユーケー リミテッド | 癌治療のために単独で用いるまたは化学療法薬と併用するヒストンデアセチラーゼ(hdac)阻害剤 |
US9382327B2 (en) * | 2006-10-10 | 2016-07-05 | Vaccinex, Inc. | Anti-CD20 antibodies and methods of use |
FR2910896B1 (fr) * | 2006-12-29 | 2012-11-16 | Lab Francais Du Fractionnement | Anticorps monoclonal dirige contre le recepteur humain des ldl |
FR2915398B1 (fr) * | 2007-04-25 | 2012-12-28 | Lab Francais Du Fractionnement | "ensemble de moyens pour le traitement d'une pathologie maligne, d'une maladie auto-immune ou d'une maladie infectieuse" |
EP1985633A1 (en) * | 2007-04-26 | 2008-10-29 | LFB Biotechnologies | Kit of parts for the treatment of cancer or infectious diseases |
CN101868446A (zh) | 2007-09-25 | 2010-10-20 | 托波塔吉特英国有限公司 | 某些异羟肟酸化合物的合成方法 |
MX2010011057A (es) | 2008-04-11 | 2010-11-12 | Trubion Pharmaceuticals Inc | Inmunoterapeutico de cd37 y combinacion con quimioterapeutico bifuncional del mismo. |
TW201438738A (zh) | 2008-09-16 | 2014-10-16 | Genentech Inc | 治療進展型多發性硬化症之方法 |
WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
FR2940616A1 (fr) * | 2008-12-30 | 2010-07-02 | Lfb Biotechnologies | Utilisation d'un anticorps anti-cd20 pour le traitement du lymphome primaire intraoculaire. |
EP2233500A1 (en) | 2009-03-20 | 2010-09-29 | LFB Biotechnologies | Optimized Fc variants |
TW201129384A (en) | 2010-02-10 | 2011-09-01 | Immunogen Inc | CD20 antibodies and uses thereof |
FR2962908A1 (fr) * | 2010-07-20 | 2012-01-27 | Lfb Biotechnologies | Formulation d'anticorps anti-cd20 |
FR2966043A1 (fr) * | 2010-10-14 | 2012-04-20 | Lfb Biotechnologies | Utilisation d'un anticorps anti-cd20 pour le traitement du lymphome cerebral primitif |
FR2976811A1 (fr) | 2011-06-22 | 2012-12-28 | Lfb Biotechnologies | Utilisation d'un anticorps anti-cd20 a haute adcc pour le traitement de la maladie de waldenstrom |
EP2537864B1 (en) | 2011-06-24 | 2019-08-07 | Laboratoire Français du Fractionnement et des Biotechnologies | Fc variants with reduced effector functions |
FR2980110A1 (fr) * | 2011-09-20 | 2013-03-22 | Lfb Biotechnologies | Combinaison d'anticorps anti-cd20 et de bendamustine |
IN2015DN00139A (xx) * | 2012-07-13 | 2015-06-12 | Univ Pennsylvania | |
EP2914343B1 (en) * | 2012-11-02 | 2019-03-06 | TG Therapeutics, Inc. | Combination of anti-cd20 antibody and pi3 kinase selective inhibitor |
JP7632835B2 (ja) * | 2016-05-20 | 2025-02-19 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 加齢関連疾患及び症状の遺伝子治療法 |
BR112018074238A2 (pt) | 2016-05-27 | 2019-04-16 | Tg Therapeutics, Inc. | combinação de anticorpo anti-cd20, inibidor de p13 quinase-delta seletivo e inibidor de btk para tratar desordens proliferativas de células b |
EP3509634A1 (en) | 2016-09-09 | 2019-07-17 | TG Therapeutics Inc. | Combination of an anti-cd20 antibody, pi3 kinase-delta inhibitor, and anti-pd-1 or anti-pd-l1 antibody for treating hematological cancers |
US20220143026A1 (en) | 2020-11-12 | 2022-05-12 | Tg Therapeutics, Inc. | Triple combination to treat b-cell malignancies |
US11814439B1 (en) | 2022-06-01 | 2023-11-14 | Tg Therapeutics, Inc. | Anti-CD20 antibody compositions |
US11807689B1 (en) | 2022-06-01 | 2023-11-07 | Tg Therapeutics, Inc. | Anti-CD20 antibody compositions |
US11884740B1 (en) | 2022-06-01 | 2024-01-30 | Tg Therapeutics, Inc. | Anti-CD20 antibody compositions |
US11965032B1 (en) | 2022-06-01 | 2024-04-23 | Tg Therapeutics, Inc. | Anti-CD20 antibody compositions |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT752248E (pt) * | 1992-11-13 | 2001-01-31 | Idec Pharma Corp | Aplicacao terapeutica de anticorpos quimericos e marcados radioactivamente contra antigenios de diferenciacao restrita de linfocitos b humanos para o tratamento do linfoma de celulas b |
CZ293355B6 (cs) * | 1997-03-14 | 2004-04-14 | Idec Pharmaceuticals Corporation | Způsob integrace genů do specifických míst genomu savčí buňky homologní rekombinací a příslušné vektorové systémy |
US8557244B1 (en) * | 1999-08-11 | 2013-10-15 | Biogen Idec Inc. | Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
US7754208B2 (en) * | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
JP2005500018A (ja) * | 2001-04-02 | 2005-01-06 | アイデック ファーマスーティカルズ コーポレイション | GnTIIIと同時発現する組換え抗体 |
US7214660B2 (en) * | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
CN102911987B (zh) | 2002-04-09 | 2015-09-30 | 协和发酵麒麟株式会社 | 基因组被修饰的细胞 |
FR2844455B1 (fr) | 2002-09-13 | 2007-12-14 | Lab Francais Du Fractionnement | Traitement des pathologies echappant a la reponse immune par des anticorps optimises |
WO2004024768A2 (fr) | 2002-09-13 | 2004-03-25 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Anticorps induisant la production de cytokines |
FR2844513B1 (fr) * | 2002-09-13 | 2007-08-03 | Lab Francais Du Fractionnement | Anticorps pour adcc et induisant la production de cytokines. |
CN1729203B (zh) | 2002-10-17 | 2014-02-19 | 根马布股份公司 | 抗cd20的人单克隆抗体 |
DE60332957D1 (de) * | 2002-12-16 | 2010-07-22 | Genentech Inc | Immunoglobulinvarianten und deren verwendungen |
CN1542132A (zh) | 2003-04-30 | 2004-11-03 | 上海新霁生物科技有限公司 | 高效表达治疗肿瘤并含有人恒定区全抗体基因的重组病毒及其用途 |
WO2005063815A2 (en) * | 2003-11-12 | 2005-07-14 | Biogen Idec Ma Inc. | Fcϝ receptor-binding polypeptide variants and methods related thereto |
FR2879204B1 (fr) * | 2004-12-15 | 2007-02-16 | Lab Francais Du Fractionnement | Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b. |
-
2004
- 2004-12-15 FR FR0413320A patent/FR2879204B1/fr not_active Expired - Lifetime
-
2005
- 2005-12-14 PL PL05825974.8T patent/PL1824887T3/pl unknown
- 2005-12-14 BR BRPI0519044A patent/BRPI0519044B8/pt active IP Right Grant
- 2005-12-14 KR KR1020137033324A patent/KR101418695B1/ko active Active
- 2005-12-14 DK DK05825974.8T patent/DK1824887T3/en active
- 2005-12-14 WO PCT/FR2005/003123 patent/WO2006064121A2/fr active Application Filing
- 2005-12-14 KR KR1020077015908A patent/KR101340192B1/ko active Active
- 2005-12-14 US US11/793,138 patent/US9234045B2/en active Active
- 2005-12-14 CN CN2005800478101A patent/CN101115772B/zh active Active
- 2005-12-14 JP JP2007546110A patent/JP4999699B2/ja active Active
- 2005-12-14 KR KR1020127000194A patent/KR20120023177A/ko not_active Ceased
- 2005-12-14 EP EP15174374.7A patent/EP2949674A1/fr not_active Ceased
- 2005-12-14 CA CA2590303A patent/CA2590303C/fr active Active
- 2005-12-14 AU AU2005315534A patent/AU2005315534B2/en active Active
- 2005-12-14 ES ES05825974.8T patent/ES2588161T3/es active Active
- 2005-12-14 EP EP05825974.8A patent/EP1824887B1/fr active Active
-
2007
- 2007-06-14 IL IL183947A patent/IL183947A0/en active IP Right Grant
-
2011
- 2011-12-16 JP JP2011276347A patent/JP5693440B2/ja active Active
-
2015
- 2015-08-17 US US14/828,177 patent/US9873745B2/en active Active
-
2023
- 2023-09-14 NL NL301242C patent/NL301242I2/nl unknown
- 2023-10-20 FR FR23C1038C patent/FR23C1038I2/fr active Active
- 2023-11-21 BE BE2023C542C patent/BE2023C542I2/fr unknown